Generic Wegovy Canada: Sevmia is approved, but you cannot buy it yet

Sevmia is the first generic Wegovy Canada has approved, and right now it exists only as a licence. Health Canada authorized it on June 29, 2026, but no pharmacy has stock, and Apotex has given no date or price^1,2,3.

This page covers what Sevmia is, why its single 1 mg pen matters, what the price signals say and what you can do while you wait. It does not tell you how to use any drug for weight loss; that call belongs to your prescriber. For how every drug plan treats semaglutide, see our coverage guide.

Is there a generic Wegovy in Canada?

Yes. Sevmia (DIN 02569582) is approved for chronic weight management, but it is not marketed, so you cannot fill it today².

Health Canada’s Drug Product Database lists Sevmia as “Approved” with no market date. That was still true at our last sync of the database on November 3, 2026².

Ontario added Sevmia to its formulary on August 31, 2026, but only as “Off-Formulary Interchangeable” with the Wegovy 1 mg pen (DIN 02528525)⁴. That listing tells pharmacists the two are interchangeable. It does not mean the pen is on shelves, and it does not mean Ontario pays for it.

What is Sevmia?

Sevmia is semaglutide injection made by Apotex, the Toronto company that also makes Apo-Semaglutide, its generic of Ozempic. Health Canada called it the first generic semaglutide for weight loss when it issued the approval¹.

What Sevmia is approved for

Sevmia’s product monograph lists two uses⁵. The first is chronic weight management, alongside a reduced-calorie diet and more physical activity. The second is lowering the risk of a non-fatal heart attack in adults with established heart disease and a body mass index (BMI) of 27 or more.

For weight management, the monograph covers adults with a BMI of 30 or more. It also covers adults with a BMI of 27 or more and at least one weight-related condition, such as high blood pressure, type 2 diabetes or sleep apnea⁵.

The monograph also covers teens aged 12 to 17 who meet set BMI and body-weight cut-offs⁵. Those are the same uses Wegovy’s monograph lists⁶.

There is a small mismatch in the public record. Health Canada’s announcement says Sevmia can be prescribed from age 12, while Apotex’s own press release talks about adults^1,3. The monograph, which is the document prescribers follow, includes the 12-to-17 group⁵.

How it is made

Wegovy is made with recombinant DNA technology in yeast cells⁶. Sevmia is “produced by solid-phase synthetic chemistry,” according to its monograph⁵.

Health Canada describes the generic semaglutides as complex synthetic products that are “pharmaceutically equivalent” to the brand biologic. It also says the review checks that any differences do not affect safety, efficacy or quality⁷. Apotex developed Sevmia with a partner, Orbicular Pharmaceutical Technologies³.

The name: Sevmia, not “Svemia”

Several news outlets printed the name as “Svemia” when the approval was announced^8,9. Health Canada’s database and Apotex both spell it Sevmia^2,3. If you search for it, or ask a pharmacist, use Sevmia.

Why Sevmia only comes in 1 mg

Sevmia has one pen, and it delivers a 1 mg dose once a week^2,5. Brand Wegovy has five dose strengths, so Sevmia covers one step of the brand’s dose ladder.

The Sevmia pen holds 4 mg of semaglutide in 3 mL (1.34 mg/mL), enough for four weekly 1 mg doses⁵. Wegovy’s monograph lists pens for 0.25 mg, 0.5 mg, 1 mg, 1.7 mg and 2.4 mg doses⁶.

What the monograph says about the dose steps

The Wegovy and Sevmia monographs describe the same schedule. Treatment starts at 0.25 mg once weekly and goes up every four weeks, through 0.5, 1 and 1.7 mg, to a maintenance dose of 2.4 mg after 16 weeks^5,6.

Sevmia’s monograph is blunt about its limit. It says Sevmia “can be prescribed only for 1 mg once weekly dosing” and that other products are needed for any other dose⁵.

What that means for a patient

Here is the practical read. The starting doses and the 2.4 mg maintenance dose are still brand-only, so Sevmia alone cannot take someone through the full schedule the monograph describes.

Whether a 1 mg pen fits your treatment, and how it would combine with other products, is a question for your prescriber. This site does not give dose advice, and nothing here should change what you inject.

When will Sevmia be sold?

There is no confirmed date. Apotex has not announced a launch, and Health Canada’s database shows no market date^2,3.

Some websites have said Sevmia will arrive in November 2026, or that it depends on another company’s ingredient supply. Neither claim could be traced to Apotex, Health Canada or a news report, so this page treats both as unconfirmed. Apotex has named Orbicular only as its development partner³.

Here is what has happened so far. Each step is on the public record:

• June 29, 2026: Health Canada issues the approval (Notice of Compliance)^1,10.
• June 30, 2026: Apotex announces it, with no price or launch date³.
• August 31, 2026: Ontario lists Sevmia as off-formulary interchangeable with the Wegovy 1 mg pen⁴.
• As of November 3, 2026: still “Approved” in Health Canada’s database, with no market date².

Our read: the paperwork is moving, but none of it is a launch date. Our generic semaglutide news page will note the change when the database status flips.

Don’t mix it up with Poviztra

Novo Nordisk also has a renamed Wegovy, called Poviztra, approved in December 2025¹⁰. It is not a generic.

Health Canada said Novo’s renamed products are identical to the originals, with no change to the formula¹¹. Every Poviztra pen is listed as approved but not marketed².

Is anyone selling generic Wegovy now?

Not as an authorized product. Because Sevmia has no market date, no Canadian pharmacy can be filling it, so a product sold today as “generic Wegovy” is not Sevmia².

A January 2026 Health Canada advisory found unauthorized GLP-1 products for sale in shops and online, and some sites even borrowed the department’s logo¹². It listed the risks: the wrong active ingredient or none at all, contamination, and injections that are not sterile¹².

Its advice is to buy only from licensed pharmacies and to look up the eight-digit DIN in the Drug Product Database¹². Today the only generic Wegovy DIN is 02569582, and its status still reads “Approved,” not “Marketed”².

Compounded semaglutide is not a shortcut either. In January 2025, Health Canada ran a Type I recall of a Calgary pharmacy’s semaglutide and pyridoxine syringes and vials, made with an unauthorized active ingredient¹³.

What generic Wegovy will cost

Nobody knows yet. Apotex has published no price for Sevmia, and no reputable outlet has reported one³.

The one listed figure

Ontario’s formulary shows a unit price of $325.05 for Sevmia, next to “N/A” in the column for what the province pays⁴. Read that as a formulary reference figure. It is not a promise of what a pharmacy will charge, and Ontario does not pay it.

For scale, the same formulary lists a generic Ozempic pen at $78.14⁴. Comparing the two is tempting but shaky, because the pens, doses and uses differ.

What brand Wegovy costs now

Experts quoted by The Canadian Press put brand Wegovy at about $400 a month⁹. Novo’s Wegovy card promises privately insured patients “up to 5% savings.” Novo adds that a 28-day supply can cost some of them as little as $300 a month¹⁴.

Our read: a generic usually lands below the brand, as Apo-Semaglutide did against Ozempic⁴. But Sevmia’s price will depend on Apotex, and this site will not guess a number. For what the generic diabetes pens cost today, see the generic semaglutide price page.

Can I use generic Ozempic for weight loss instead?

The generic Ozempic products are authorized for adults with type 2 diabetes⁷. Any use for weight management is off-label, and whether that is right for you is your prescriber’s decision.

People ask because the molecule is the same. Generic Ozempic and Sevmia both contain semaglutide, but they were authorized for different conditions and come in different pens and doses. No generic delivers a 2 mg Ozempic dose, and none delivers Wegovy’s 1.7 mg or 2.4 mg doses².

Insurers draw the same line. Medavie Blue Cross says generic Ozempic “will not be approved as a substitute” for Wegovy¹⁵. For the diabetes generics on the market, see the generic Ozempic overview, and for how those pens compare with the brand, our generic vs Ozempic comparison.

Will insurance cover generic Wegovy?

Not through any public plan, and private coverage depends on your policy. The plan-by-plan coverage page has the details for diabetes as well.

The public plans’ bargaining group, the pan-Canadian Pharmaceutical Alliance, closed its Wegovy talks on December 1, 2025 with no deal. BC’s coverage decision records that the manufacturer declined to negotiate¹⁶. Novo Nordisk said it would no longer pursue public funding for Wegovy, as Global News also reported^16,17.

BC lists Wegovy as a non-benefit. Its December 2025 decision cites an expert committee that backed coverage only for people with a BMI of 27 or more and established heart disease. Even then, the committee wanted a price cut¹⁶.

The same document says BC will look at generic semaglutide filings once they are on the market¹⁶.

Ontario lists Sevmia as off-formulary, so the Ontario Drug Benefit does not pay for it⁴. On the private side, some plans cover weight-management drugs and some do not. Once Sevmia has a launch date, ask your insurer whether it will be treated the same as Wegovy.

Other generic Wegovy filings

Nobody outside Health Canada knows how many more Wegovy copies are coming. The public list of generic submissions shows nine semaglutide files under review as of August 31, 2026, but it does not say which brand each one copies¹⁸.

All of those files sit under the heading “Drugs used in diabetes”¹⁸. That heading is a broad therapeutic class, so it does not rule out a weight-management product. Apotex itself had another semaglutide submission accepted for review in July 2026, and its product type is not public either¹⁸.

The honest answer: Sevmia is still the only generic Wegovy Canada has signed off on. Any other one will show up first as a Health Canada approval, and we will add it when it does.

What to do while you wait for Sevmia

The right move depends on where you are now. Here is how the options sort out, based on the documents above.

• You are on brand Wegovy now: stay with your current plan of care until your prescriber says otherwise. If you have private insurance, ask whether Novo’s Wegovy savings card applies to you.
• Your dose is 1 mg weekly: ask your prescriber and pharmacist to flag Sevmia when it launches, since that is the one dose it covers. Whether to switch is their call, made with you.
• You are on a different Wegovy dose: Sevmia will not replace your pen at launch, because it comes only in 1 mg. Your prescriber can explain what that means for your plan.
• You were offered generic Ozempic for weight loss: that is off-label use. Ask your prescriber why they suggest it and what monitoring comes with it.
• You are not on Wegovy yet but have private insurance: call your insurer and ask whether it covers Wegovy at all, and whether it plans to cover a generic.

If you want to compare how Canadians are getting semaglutide today, by pharmacy or online, take the three-question route finder. It covers the diabetes generics marketed now, and it will add Sevmia once a pharmacy can fill it.